57333-96-7 Usage
Description
Tacalcitol is a vitamin D analog developed as a topical antipsoriatic medication, specifically designed to treat various skin conditions such as keratosis, psoriasis, ichthyosis, pityriasis rubra pilaris, palmoplantar pustulosis, and keratoderma. It has demonstrated significant improvement in the appearance of skin lesions for psoriasis patients without causing significant side effects. Tacalcitol effectively inhibits keratinocyte growth in patients with psoriasis vulgaris and has shown to suppress interleukin-1-α-induced granulocyte macrophage colony-stimulating-factor mRNA expression in human dermal microvascular endothelial cells, potentially playing a role in mediating angioproliferation in skin inflammation. It is commercially available under the brand name Bonalfa.
Uses
Used in Dermatology:
Tacalcitol is used as a topical antipsoriatic agent for the treatment of various skin conditions, including keratosis, psoriasis, ichthyosis, pityriasis rubra pilaris, palmoplantar pustulosis, and keratoderma. It helps improve the appearance of skin lesions in psoriasis patients and effectively inhibits keratinocyte growth, providing relief from the symptoms of these skin conditions.
Used in Pharmaceutical Industry:
Tacalcitol is used as an active pharmaceutical ingredient in the development of medications for the treatment of skin disorders. Its effectiveness in improving skin lesions and inhibiting keratinocyte growth makes it a valuable component in the formulation of topical antipsoriatic drugs.
Used in Research and Development:
Tacalcitol is used as a research compound for studying the effects of vitamin D analogs on skin health and the underlying mechanisms of various skin conditions. Its ability to inhibit interleukin-1-α-induced granulocyte macrophage colony-stimulating-factor mRNA expression in human dermal microvascular endothelial cells makes it an important tool for understanding the role of angioproliferation in skin inflammation and the potential therapeutic applications of vitamin D analogs in dermatology.
Originator
Teijin
(Japan)
Safety Profile
A poison by ingestion, subcutaneous, and intravenous routes. When heated to decomposition it emits acrid smoke and irritating vapors,
Check Digit Verification of cas no
The CAS Registry Mumber 57333-96-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,3,3 and 3 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 57333-96:
(7*5)+(6*7)+(5*3)+(4*3)+(3*3)+(2*9)+(1*6)=137
137 % 10 = 7
So 57333-96-7 is a valid CAS Registry Number.
InChI:InChI=1/C27H44O3/c1-17(2)25(29)13-8-18(3)23-11-12-24-20(7-6-14-27(23,24)5)9-10-21-15-22(28)16-26(30)19(21)4/h9-10,17-18,22-26,28-30H,4,6-8,11-16H2,1-3,5H3/b20-9+,21-10-/t18-,22-,23-,24+,25-,26+,27-/m1/s1
57333-96-7Relevant articles and documents
Process Development of Tacalcitol
Lee, Seung Jong,Moon, Hyung Wook,Lee, Kee-Young,Oh, Chang Young,Kim, U Bin,Shin, Hyunik
, p. 982 - 987 (2021/03/15)
A highly convergent, gram-scale synthesis of vitamin D3 analogue tacalcitol 1 is disclosed, starting from L-valine and Inhoffen-Lythgoe diol. Key features of the synthesis include modified Julia olefination reaction of β-oxybenzothiazol-2-yl sulfone with C/D ring containing aldehyde to access decagrams of fully functionalized C/D ring synthon. The Horner-Wadsworth-Emmons (HWE) reaction between the C/D ring fragment and commercially available phosphonate completes the carbo-skeleton, which is elaborated into tacalcitol 1 in a gram-scale synthesis.
Enantiomeric impurity PY2 of tacalcitol and preparation method and application thereof
-
, (2018/05/30)
The invention discloses an enantiomeric impurity PY2 of tacalcitol, i.e., (1 alpha, 3 beta, 5Z, 7E, 24S)-9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, and a preparation method thereof, and belongsto the technical field of chemical pharmaceutical. The high-purity relevant impurity PY2 of the tacalcitol, which is disclosed by the invention, can be used as an impurity standard substance in the tacalcitol finished product detection analysis so as to promote accurate positioning and nature determination of the tacalcitol finished product detection analysis on the impurity and benefit reinforcement of control on the impurity, thereby improving quality of a tacalcitol finished product. The method provided by the invention has the advantages that the raw materials are cheap and easy to obtain, the operation is simple, the reproducibility is good in and the HPLC (High Performance Liquid Chromatography) purity is greater than or equal to 99.5%.
A he cassie is mellow method for the preparation of
-
, (2016/10/09)
The invention discloses a method for preparing tacalcitol. The method comprises the following steps: with a compound I as a starting raw material, carrying out Wittig reaction, CBS catalytic asymmetric reduction, hydroxy protection, hydrogenation reduction, desilication ether protection and oxidation reaction to prepare a compound VIII, carrying out Wittig Horner reaction on the compound VIII and a known compound IX for coupling, and carrying out dehydroxylation protection to obtain the target compound, namely tacalcitol. With cheap raw materials as the starting point, the method disclosed by the invention is simple, convenient and safe, steps unfavorable to amplification, such as illumination reaction and sodium amalgam reduction reaction, are avoided, and industrial production is facilitated.